Filter By Industry
Filter By Tag

Newsroom

SFA Therapeutics, Inc. Press releases

1 - 5 of 5 Press Releases

SFA Therapeutics Announces FDA Approval To Begin IND Trial
Jun 29, 2020
Clinical Trial Examines Human Micro-biome-based Drug SFA002 In Mild to Moderate Plaque Psoriasis

SFA Therapeutics Receives Grant For Drug for Acute Respiratory Distress Syndrome In COVID-19
Jun 24, 2020
New SFA005 ARDS Study Takes Aim at Management of COVID-19 Related Cytokine Storm

SFA Therapeutics, Inc. Receives an FDA Orphan Drug Designation (ODD) for SFA001 in the Treatment of Hepatocellular Carcinoma (HCC)
Oct 28, 2019
SFA Therapeutics, Inc. announced today that FDA has granted an official Orphan Drug Designation (ODD) to SFA001, the company's novel human-microbiome-based treatment for human hepatocellular carcinoma (HCC).

SFA Therapeutics, Inc. To Present At The Microbiome R&D and Business Collaboration Forum
Oct 25, 2019
Will Report on Clinical Development Plans for Multiple Promising Therapeutics Derived from Human Microbiome

SFA Therapeutics, Inc. To Present At Bio Investors Forum
Oct 18, 2019
Will Present Clinical Development Plans For Several Novel Therapeutic Agents Derived from Human Microbiome


SFA Therapeutics, Inc. RSS Feed